These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29154981)

  • 1. Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.
    Mora Vidal R; Regufe da Mota S; Hayden A; Markham H; Douglas J; Packham G; Crabb SJ
    Urology; 2018 Feb; 112():225.e1-225.e7. PubMed ID: 29154981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.
    Tsai YC; Ho PY; Tzen KY; Tuan TF; Liu WL; Cheng AL; Pu YS; Cheng JC
    Mol Cancer Ther; 2015 Mar; 14(3):810-20. PubMed ID: 25589492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
    Nicholl SM; Roztocil E; Davies MG
    J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
    Kassouf W; Dinney CP; Brown G; McConkey DJ; Diehl AJ; Bar-Eli M; Adam L
    Cancer Res; 2005 Nov; 65(22):10524-35. PubMed ID: 16288045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.
    Walters DM; Lindberg JM; Adair SJ; Newhook TE; Cowan CR; Stokes JB; Borgman CA; Stelow EB; Lowrey BT; Chopivsky ME; Gilmer TM; Parsons JT; Bauer TW
    Neoplasia; 2013 Feb; 15(2):143-55. PubMed ID: 23441129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
    Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.
    Mu Y; Sun D
    Med Sci Monit; 2018 Aug; 24():5811-5819. PubMed ID: 30125265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH; Seong MA; Lee HY
    Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.
    Li J; Lin B; Li X; Tang X; He Z; Zhou K
    Oncol Rep; 2015 Feb; 33(2):951-7. PubMed ID: 25482142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG
    Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis-related molecular differences for response to tyrosin kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.
    Li J; Lv B; Li X; He Z; Zhou K
    J Cancer Res Ther; 2013; 9(4):668-71. PubMed ID: 24518715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.
    McHugh LA; Sayan AE; Mejlvang J; Griffiths TR; Sun Y; Manson MM; Tulchinsky E; Mellon JK; Kriajevska M
    Int J Oncol; 2009 Apr; 34(4):1155-63. PubMed ID: 19287975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study.
    Jabbarzadeh Kaboli P; Leong MP; Ismail P; Ling KH
    Pharmacol Rep; 2019 Feb; 71(1):13-23. PubMed ID: 30343043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.
    Sambade MJ; Kimple RJ; Camp JT; Peters E; Livasy CA; Sartor CI; Shields JM
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):575-81. PubMed ID: 20457354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interacting post-muscarinic receptor signaling pathways potentiate matrix metalloproteinase-1 expression and invasion of human colon cancer cells.
    Said AH; Hu S; Abutaleb A; Watkins T; Cheng K; Chahdi A; Kuppusamy P; Saxena N; Xie G; Raufman JP
    Biochem J; 2017 Feb; 474(5):647-665. PubMed ID: 28008134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.
    Becker MN; Wu KJ; Marlow LA; Kreinest PA; Vonroemeling CA; Copland JA; Williams CR
    Urol Oncol; 2014 Apr; 32(3):317-26. PubMed ID: 24054871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p85β alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair.
    Mak VC; Li X; Rao L; Zhou Y; Tsao SW; Cheung LW
    Neoplasia; 2021 Jul; 23(7):718-730. PubMed ID: 34144267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.